Post Content
Kodiak Sciences Inc. (NASDAQ:KOD) is one of the
8 Healthcare Stocks Insiders Are Buying. On April 1, 2026, Kodiak Sciences Inc. (NASDAQ:KOD) reported Q4 EPS of ($1.05) compared to (84c) last year. Victor Perlroth, M.D., Chief Executive Officer, said momentum is building, citing “positive Phase 3 topline results” from the GLOW2 study and progress across late-stage and pipeline programs supporting the company’s long-term strategy.
On March 27, 2026, UBS raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $80 from $50 previously and maintained a Buy rating on the shares. UBS said it is bullish on both tarcocimab VEGF and IL6.
Photo by José Antonio Otegui Auzmendi on Pexels
Similarly, H.C. Jefferies raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $56 from $39 previously and maintained a Buy rating on the shares, noting GLOW2 results showed improved safety and efficacy versus GLOW1, with the reformulation seen as a safety improvement and potential driver of durability in the Phase III DAYBREAK study, while also supporting earlier Biologics License Application timing.
Kodiak Sciences Inc. (NASDAQ:KOD) develops therapies for retinal diseases.
While we acknowledge the potential of KOD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.